• MOVE-FA Study for PTC-743

    Posted by Christina Cordaro on April 1, 2021 at 7:48 am

    Enrollment is open at sites in the U.S., Canada, and Australia.

    MOVE-FA is a Phase 2/3 interventional study that will monitor the safety and efficacy of the drug Vatiquinone. This 2-year study is sponsored by PTC Therapeutics. Eligibility criteria include:

    -Genetically confirmed FA with two GAA repeat expansions (currently, point mutations and deletions are excluded from the study)
    -Children ages 7-17 and Adults age 18 and older
    -Ability to walk 10 feet in one minute (can use assitive devices of cane or walker; no wheelchair)
    -Be able to swallow capsules
    -Not have participated in another interventional study in the 2 months prior to enrollment in MOVE-FA

    Information on MOVE-FA and contacts for study coordinators can be found below: bit.ly/36YC9t6

    Christina Cordaro replied 3 years, 3 months ago 1 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.